Corline Biomedical Q3 (Initial take): No sales ramp-up this quarter, but only a matter of time - Redeye

Redeye provides an initial take following the release of Corline’s Q3 2025 report. Sales came in lower than expected; however, we see no cause for concern and expect the Kardium-driven ramp-up to become more evident in upcoming reports. We will publish a research update, where some minor estimate revisions may be made, but we do not anticipate any material impact on our valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139622/corline-biomedical-q3-initial-take-no-sales-ramp-up-this-quarter-but-only-a-matter-of-time?utm_source=finwire&utm_medium=RSS